How will I know if my HER2-Positive Breast Cancer treatment is working

How to Know If Your HER2-Positive Breast Cancer Treatment Is Working

This is one of the most important questions you can ask your care team. Let me explain the main ways doctors monitor treatment response and what you should be watching for.

The Standard Monitoring Approach

According to the CancerPatientLab webinars on clinical guidance, doctors typically use imaging and blood tests at regular intervals (usually every 3 months) to assess how your treatment is performing. Here's what they're looking for:

1. Imaging Studies (CT scans, MRI, PET scans)

• These show whether tumors are shrinking, staying stable, or growing
• Doctors compare images over time to measure changes in tumor size
• A key limitation: imaging can typically only detect tumors about the size of a cubic centimeter (roughly a billion cancer cells), so very early changes might not show up immediately

2. Tumor Markers in Your Blood

• Your doctor may track CA 15-3 or CEA (carcinoembryonic antigen) levels
• These are proteins released by cancer cells that appear in the bloodstream
• Declining levels generally suggest the cancer is responding to treatment
• Rising levels may indicate the cancer is progressing

3. Physical Symptoms

• Improvement in pain, swelling, or other symptoms you were experiencing
• Better energy levels and overall feeling of wellness
• Ability to return to normal activities

HER2-Specific Monitoring Considerations

Since you have HER2-positive breast cancer, your treatment likely includes anti-HER2 therapies like trastuzumab (Herceptin) or trastuzumab deruxtecan (Enhertu). According to the proteomics guidance from the webinars, HER2 protein levels are particularly important because:

• High HER2 expression responds well to anti-HER2 targeted therapies
• Doctors may measure HER2 levels through specialized testing (like mass spectrometry from tissue samples) to confirm your cancer's HER2 status and predict treatment response
• Some patients with very high HER2 expression have shown excellent long-term survival (6-7 years without cancer events) when treated with anti-HER2 therapy

Emerging Monitoring Tools

The webinars highlight newer approaches that may complement traditional imaging:

Liquid Biopsies (Blood Tests)

• These measure circulating tumor DNA (ctDNA) or circulating tumor cells (CTCs) in your bloodstream
• They can potentially detect treatment response earlier than imaging
• This is still an evolving area, but some centers now use these for response monitoring

Proteomics Testing

• Specialized protein analysis can predict overall survival and treatment response
• Results typically available within 5 days of testing
• Can help guide treatment decisions if you're not responding as expected

Important Questions to Ask Your Oncologist

To develop a clear monitoring plan specific to your situation:

1. "What is my baseline tumor burden, and what are we measuring to track response?" (specific tumor sizes, marker levels, etc.)

2. "How often will we do imaging and blood tests, and what timeline should we expect to see response?" (Some cancers respond within weeks; others take months)

3. "What constitutes a 'good response' for my specific stage and type of HER2-positive cancer?" (Complete response vs. partial response vs. stable disease)

4. "If my cancer isn't responding as expected, what additional testing (like liquid biopsy or proteomics) might help guide next steps?"

5. "Are there any clinical trials using newer monitoring methods that might be appropriate for me?"

6. "What symptoms or changes should I report immediately between appointments?"

What "Response" Actually Means

According to the clinical guidance, treatment response is typically categorized as:

• Complete Response: Cancer is no longer detectable on imaging
• Partial Response: Tumor has shrunk by at least 30% in size
• Stable Disease: Tumor hasn't grown or shrunk significantly, but treatment is holding it in check
• Progressive Disease: Tumor is growing despite treatment

Important context: As the webinars emphasize, just because you can detect something early doesn't automatically mean earlier detection improves your outcome. What matters is having treatment options available and making smart choices about which ones to use based on your specific cancer's characteristics.

The Bottom Line

Treatment monitoring for HER2-positive breast cancer involves a combination of imaging, blood tests, and symptom assessment at regular intervals. Your oncologist will compare results over time to determine if your treatment is working. If you're not seeing the response you'd expect, discuss additional testing options like liquid biopsies or proteomics analysis that might provide more detailed information about your cancer's behavior.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.